Prospective evaluation of recombinant Herpes zoster vaccine in systemic sclerosis: immunogenicity, safety, and disease outcomes
Clicks: 2
ID: 316581
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #187 of 206 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 206 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: to evaluate humoral immune response to recombinant zoster vaccine(RZV) in immunosuppressed patients with systemic sclerosis(SSc) compared with healthy controls, to identify factors influencing vaccine response, and to assess RZV safety and impact on patient-reported outcome measures(PROMs) and disease activity(DA). METHODS: A sub-analysis of a randomized, double-blind, placebo-controlled trial included 76 immunosuppressed SSc patients and 304 healthy controls(CG) receiving two RZV doses. SSc patients were randomized to receive two initial doses of RZV or placebo; after unblinding, the placebo group received two doses of RZV. Anti-glycoprotein-E antibodies were measured at baseline and six-weeks post-second dose. Geometric mean concentrations(GMCs) and factor increase(FI) were calculated. Cell-mediated immunogenicity (CMI) was evaluated. DA and PROMs were assessed using standardized instruments. Body mass index(BMI) defined nutritional status. RESULTS: SSc patients(47.4%diffuse/52.6%limited) were younger(53.0 vs 55.0 years, p= 0.002) and had lower BMI(p= 0.005) than CG. Humoral response were significantly lower in SSc compared with controls(92.6% vs 99.7%,p= 0.001). SSc patients showed significantly lower GMC(5.81 vs 12.6, p< 0.001) and FI(31.0 vs 59.4, p< 0.001) than controls, with comparable CMI(p> 0.05). Disease subtypes, demographic factors, immunosuppressive therapies or nutritional status did not predict impaired vaccine response(p> 0.05). Local adverse events were reduced in SSc patients(73.7% vs 86.5%,p= 0.024), while systemic reactions were comparable overall(59.2% vs 61.5%,p= 0.712). DA and PROMs outcomes remained stable(p> 0.05). CONCLUSION: RZV was well tolerated. Despite the high seroconversion rate, the immune response was significantly lower in magnitude compared with controls, without triggering DA or worsening PROMs. ∼50% lower antibody concentrations in SS raise concerns about long-term protection, underscoring the need for ongoing monitoring. TRIAL REGISTRATION: ClinicalTrials.gov; NCT05879419.
| Reference Key |
openalex_W7164011987
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ana Paula Luppino-Assad, Renata P Mello, Ana Cristina Medeiros-Ribeiro, Nádia Emi Aikawa, Sandra Gofinet Pasoto, Ana Clara Praxedes, Léonard de Vinci Kanda Kupa, Renata Miossi, Percival D. Sampaio‐Barros, Eduardo Ferreira Borba, Eloísa Bonfá, Clóvis A. Silva |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag294
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.